Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia

  Galectin Therapeutics Announces Discovery Program for New Anti-Galectin
  Drugs in Collaboration with the University of Georgia

Business Wire

NORCROSS, Ga. -- February 19, 2013

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, announced today
the establishment of a collaborative drug discovery program with Dr. Geert-Jan
Boons’ laboratory located in the Complex Carbohydrate Research Center at the
University of Georgia. This program is focused on the discovery of new
carbohydrate molecules that can be used in the therapy of diseases where
galectin proteins play a major role, including cancer and inflammatory and
fibrotic disorders.

“Galectins play a critical role in many diseases and developing a pipeline of
drugs that can target galectins is an important goal as follow-on compounds
for our drugs currently in development and to extend the potential indications
and routes of administration,” said Peter G. Traber, MD, President, Chief
Executive Officer and Chief Medical Officer, Galectin Therapeutics. “We are
extremely excited about our collaboration with the world-class Complex
Carbohydrate Research Center and Dr. Boons, who is a world renowned and
preeminent carbohydrate chemist. There is no better place in the world to
conduct these investigations than the University of Georgia.”

“Galectin Therapeutics’ expertise in galectin science and drug discovery and
the ability of my laboratory to prepare panels of complex carbohydrates
provides an ideal combination of scientific expertise to develop the next
generation of therapeutics for fibrosis and cancer,” said Dr. Geert-Jan Boons
of the Complex Carbohydrate Research Center.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at www.galectintherapeutics.com.

About Complex Carbohydrate Research Center, University of Georgia

The Complex Carbohydrate Research Center was founded at the University of
Georgia in 1985, and is one of only three centers worldwide dedicated to the
study of complex carbohydrates, which play critical roles in cellular
communication, gene expression, immunology, organism defense mechanisms,
growth and development. The 140,000-square-foot facility is home to 17
interdisciplinary research groups, including four federally designated centers
for carbohydrate research. In addition to UGA research projects, the center
also provides analytical services and training to university, government and
industrial scientists interested in complex carbohydrate molecules. For more
information, see www.ccrc.uga.edu.

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.

Contact:

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com
or
University of Georgia
James Hataway, 706-542-5222
Research Communications
jhataway@uga.edu